Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuRPE Cells Transplantation in Retinitis Pigmentosa and Leber Congenital Amaurosis
NCT03566147Phase 1Unknown
- Sponsor
- Eyecure Therapeutics Inc.
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of Human primary Retinal Pigment Epithelial cells in retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) (3 arms), sponsored by Eyecure Therapeutics Inc. Primary endpoint: Best-Corrected Visual Acuity at 12 months. Status: unknown.
02
Drugs
Human primary Retinal Pigment Epithelial cells
03
Conditions
retinitis pigmentosa (RP)Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT03566147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03566147.